In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential ...

For Melanoma Awareness Month, Dr. Douglas Johnson explains how stage and features of the disease can guide treatment decisions after diagnosis. In recognition of Melanoma Awareness Month, CURE spoke ...

COLORADO SPRINGS — May is Skin Cancer Awareness Month, and medical professionals are sounding the alarm about melanoma, one of the deadliest forms of skin cancer. The silver lining? When caught ...

The clinical approach, epidemiology, diagnostic procedures, and management, along with followup of superficial spreading malignant melanoma are discussed. A 45-year-old Caucasian female presented ...

At OMA in the 1980s, Rem Koolhaas and his early colleagues, such as Elia Zenghelis, incorporated the diagram into the wealth of drawing types used by architects to create work. Added to the repertoire ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.

MELANOMA REMAINS a formidable challenge in oncology, particularly in its advanced stages. Over the past decade, however, the treatment landscape has transformed with immune checkpoint inhibitors (ICIs ...

A common virus carried by approximately half of adults worldwide may improve outcomes for melanoma patients receiving immunotherapy while also protecting against severe treatment-related side effects ...

(Gray News) - A brown line on a mother’s fingernail turned out to be a rare form of melanoma, according to the Cleveland Clinic. Lauren Koltcz, 45, said she noticed a brown streak on her thumbnail one ...

The 2-year recurrence-free survival rate was 98.6% in the dabrafenib-trametinib group, 84.3% in the observation group, and 79.3% in the anti-PD-1 group. Adjuvant treatment with dabrafenib and ...